219 related articles for article (PubMed ID: 34704241)
21. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
22. Incidence of respiratory syncytial virus bronchiolitis in hospitalized infants born at 33-36 weeks of gestational age compared with those born at term: a retrospective cohort study.
Greenberg D; Dagan R; Shany E; Ben-Shimol S; Givon-Lavi N
Clin Microbiol Infect; 2020 Feb; 26(2):256.e1-256.e5. PubMed ID: 31181285
[TBL] [Abstract][Full Text] [Related]
23. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
[TBL] [Abstract][Full Text] [Related]
24. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
25. Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States.
Goldstein M; Fergie J; Krilov LR
Infect Dis Ther; 2021 Mar; 10(Suppl 1):17-26. PubMed ID: 33656649
[TBL] [Abstract][Full Text] [Related]
26. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
28. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
29. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
[No Abstract] [Full Text] [Related]
30. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
31. Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.
Pavilack M; Clifford RA; Gonzales T; Kong AM; Wade S; McLaurin KK
Infect Dis Ther; 2018 Mar; 7(1):121-134. PubMed ID: 29149439
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
33. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
[TBL] [Abstract][Full Text] [Related]
34. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
35. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
[TBL] [Abstract][Full Text] [Related]
36. Severity and Cost of RSV Hospitalization Among US Preterm Infants Following the 2014 American Academy of Pediatrics Policy Change.
Krilov LR; Forbes ML; Goldstein M; Wadhawan R; Stewart DL
Infect Dis Ther; 2021 Mar; 10(Suppl 1):27-34. PubMed ID: 33656650
[TBL] [Abstract][Full Text] [Related]
37. Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
Sarna M; Gebremedhin A; Richmond P; Levy A; Glass K; Moore HC
Vaccine; 2023 Aug; 41(36):5216-5220. PubMed ID: 37474407
[TBL] [Abstract][Full Text] [Related]
38. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
[TBL] [Abstract][Full Text] [Related]
39. Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study.
Silvestri M; Marando F; Costanzo AM; di Luzio Paparatti U; Rossi GA
Ital J Pediatr; 2016 Apr; 42():40. PubMed ID: 27112952
[TBL] [Abstract][Full Text] [Related]
40. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants.
Farber HJ; Buckwold FJ; Lachman B; Simpson JS; Buck E; Arun M; Valadez AM; Ruiz T; Alonzo J; Henry A; Cos-Okpalla N; Nguyen K; Brendel W; Small J; Glomb WB
Pediatrics; 2016 Aug; 138(2):. PubMed ID: 27432850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
